EUVIMEDEUVIMED entdecken
Übersichtsarbeit

From cells to organoids: The evolution of blood-brain barrier technology for modelling drug delivery in brain cancer

Estrella Gonzales-Aloy, Aria Ahmed-Cox, Maria Tsoli, David S Ziegler, Maria Kavallaris

Advanced Drug Delivery Reviews · 2023-05 · 196 · 114777

DOI: 10.1016/j.addr.2023.114777 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advanced Drug Delivery Reviews, 2023-05. Verfasst von Estrella Gonzales-Aloy und 4 weiteren Autor:innen. Beteiligte Einrichtung: Children's Cancer Institute, Lowy Cancer Research Center, UNSW Sydney, NSW, Australia; Australian Center for NanoMedicine, UNSW Sydney, NSW, Australi…. Hauptthemen laut MEDLINE: Blood-Brain Barrier, Brain Neoplasms. Die Arbeit wurde bisher 58-mal zitiert (Crossref) und nennt 289 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Brain cancer remains the deadliest cancer. The blood-brain barrier (BBB) is impenetrable to most drugs and is a complex 3D network of multiple cell types including endothelial cells, astrocytes, and pericytes. In brain cancers, the BBB becomes disrupted during tumor progression and forms the blood-brain tumor barrier (BBTB). To advance therapeutic development, there is a critical need for physiologically relevant BBB in vitro models. 3D cell systems are emerging as valuable preclinical models to accelerate discoveries for diseases. Given the versatility and capability of 3D cell models, their potential for modelling the BBB and BBTB is reviewed. Technological advances of BBB models and challenges of in vitro modelling the BBTB, and application of these models as tools for assessing therapeutics and nano drug delivery, are discussed. Quantitative, in vitro BBB models that are predictive of effective brain cancer therapies will be invaluable for accelerating advancing new treatments to the clinic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood-Brain BarrierBrain NeoplasmsHumansEndothelial CellsBrainOrganoids

Stichwörter der Autor:innen

Blood–brain tumor barrierDrug deliveryDrug screeningGlioblastomaMicrofluidicsNanoparticlesOrganoidSpheroidTranswell

Autor:innen und Institutionen

  • Children's Cancer Institute, Lowy Cancer Research Center, UNSW Sydney, NSW, Australia; Australian Center for NanoMedicine, UNSW Sydney, NSW, Australia; School of Clinical Medicine, Faculty of Medicine and Health, UNSW S…
  • Children's Cancer Institute, Lowy Cancer Research Center, UNSW Sydney, NSW, Australia; School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, NSW, Australia.
  • Children's Cancer Institute, Lowy Cancer Research Center, UNSW Sydney, NSW, Australia; School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, NSW, Australia; Kids Cancer Center, Sydney Children's Hosp…

Zitieren

APA

Gonzales-Aloy, E., Ahmed-Cox, A., Tsoli, M., Ziegler, D. S., & Kavallaris, M. (2023). From cells to organoids: The evolution of blood-brain barrier technology for modelling drug delivery in brain cancer. Advanced Drug Delivery Reviews, 196, 114777. https://doi.org/10.1016/j.addr.2023.114777

Vancouver

Gonzales-Aloy E, Ahmed-Cox A, Tsoli M, Ziegler DS, Kavallaris M. From cells to organoids: The evolution of blood-brain barrier technology for modelling drug delivery in brain cancer. Advanced Drug Delivery Reviews. 2023;196:114777. doi:10.1016/j.addr.2023.114777

BibTeX
@article{GonzalesAloy2023,
  author = {Gonzales-Aloy, Estrella and Ahmed-Cox, Aria and Tsoli, Maria and Ziegler, David S and Kavallaris, Maria},
  title = {From cells to organoids: The evolution of blood-brain barrier technology for modelling drug delivery in brain cancer},
  journal = {Advanced Drug Delivery Reviews},
  year = {2023},
  volume = {196},
  pages = {114777},
  doi = {10.1016/j.addr.2023.114777}
}
Kostenlos starten →